CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients
June 25, 2026
June 25, 2026
PHILADELPHIA, Pennsylvania, June 25 -- The University of Pennsylvania posted the following news:
* * *
CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients
*
After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel-the CAR T cell therapy developed by Carl June, that would go on to . . .
* * *
CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients
*
After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel-the CAR T cell therapy developed by Carl June, that would go on to . . .